Výsledky vyhľadávania - "ANTICHOLESTEREMIC agents"

Ezetimibe and the risk of new-onset type 2 diabetes: a systematic review and meta-analysis.

Autori: Albawa'neh AS Alqasrawi MN Al-Mahayri ZN a ďalší

Zdroj: Annals of medicine [Ann Med] 2025 Dec; Vol. 57 (1), pp. 2594355. Date of Electronic Publication: 2025 Nov 30.

Spôsob vydávania: Journal Article; Systematic Review; Meta-Analysis

Informácie o časopise: Publisher: Informa Healthcare Country of Publication: England NLM ID: 8906388 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1365-2060 (Electronic) Linking ISSN: 07853890 NLM ISO Abbreviation: Ann Med Subsets: MEDLINE

Výrazy zo slovníka MeSH: Diabetes Mellitus, Type 2*/epidemiology , Diabetes Mellitus, Type 2*/chemically induced , Diabetes Mellitus, Type 2*/prevention & control , Ezetimibe*/therapeutic use , Ezetimibe*/adverse effects , Ezetimibe*/administration & dosage , Anticholesteremic Agents*/therapeutic use , Anticholesteremic Agents*/adverse effects , Anticholesteremic Agents*/administration & dosage , Hydroxymethylglutaryl-CoA Reductase Inhibitors*/therapeutic use , Hydroxymethylglutaryl-CoA Reductase Inhibitors*/adverse effects , Hydroxymethylglutaryl-CoA Reductase Inhibitors*/administration & dosage, Humans ; Drug Therapy, Combination ; Cardiovascular Diseases/prevention & control ; Observational Studies as Topic ; Risk Factors

The two faces of cholesteryl ester transfer protein inhibitors.

Autori: Pirillo A Catapano AL

Zdroj: Current opinion in lipidology [Curr Opin Lipidol] 2025 Dec 01; Vol. 36 (6), pp. 318-325. Date of Electronic Publication: 2025 Oct 13.

Spôsob vydávania: Journal Article; Review

Informácie o časopise: Publisher: Lippincott Williams & Wilkins Country of Publication: England NLM ID: 9010000 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1473-6535 (Electronic) Linking ISSN: 09579672 NLM ISO Abbreviation: Curr Opin Lipidol Subsets: MEDLINE

Výrazy zo slovníka MeSH: Cholesterol Ester Transfer Proteins*/antagonists & inhibitors , Cholesterol Ester Transfer Proteins*/metabolism , Anticholesteremic Agents*/therapeutic use , Anticholesteremic Agents*/pharmacology, Humans ; Animals ; Atherosclerosis/drug therapy ; Atherosclerosis/metabolism

Cost-effectiveness of non-statin lipid-lowering therapies as an add-on to statins for achieving low-density lipoprotein cholesterol therapeutic targets in very high-risk patients in the Spanish setting.

Autori: Climente-Martí M García-González X Torres-Bondia FI a ďalší

Zdroj: Journal of medical economics [J Med Econ] 2025 Dec; Vol. 28 (1), pp. 1857-1868. Date of Electronic Publication: 2025 Oct 25.

Spôsob vydávania: Journal Article

Informácie o časopise: Publisher: Taylor & Francis Country of Publication: England NLM ID: 9892255 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1941-837X (Electronic) Linking ISSN: 13696998 NLM ISO Abbreviation: J Med Econ Subsets: MEDLINE

Výrazy zo slovníka MeSH: Cholesterol, LDL*/blood , Hydroxymethylglutaryl-CoA Reductase Inhibitors*/therapeutic use , Hydroxymethylglutaryl-CoA Reductase Inhibitors*/economics , Hydroxymethylglutaryl-CoA Reductase Inhibitors*/administration & dosage , Anticholesteremic Agents*/economics , Anticholesteremic Agents*/therapeutic use , Anticholesteremic Agents*/administration & dosage , Dyslipidemias*/drug therapy, Humans ; Cost-Benefit Analysis ; Antibodies, Monoclonal, Humanized/economics ; Antibodies, Monoclonal, Humanized/therapeutic use ; Spain ; Male ; Female ; Drug Therapy, Combination ; Cardiovascular Diseases/prevention & control ; Middle Aged ; Secondary Prevention/economics ; Secondary Prevention/methods ; Monte Carlo Method ; Aged ; PCSK9 Inhibitors

Rationale and design of the REMBRANDT trial: A phase 3 study to evaluate the effect of obicetrapib/ezetimibe on coronary plaque characteristics.

Autori: McCarthy CP Ballantyne CM Blankstein R a ďalší

Zdroj: American heart journal [Am Heart J] 2025 Dec; Vol. 290, pp. 325-338. Date of Electronic Publication: 2025 Jul 17.

Spôsob vydávania: Clinical Trial, Phase III; Journal Article; Randomized Controlled Trial

Informácie o časopise: Publisher: Mosby Country of Publication: United States NLM ID: 0370465 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1097-6744 (Electronic) Linking ISSN: 00028703 NLM ISO Abbreviation: Am Heart J Subsets: MEDLINE

Výrazy zo slovníka MeSH: Anticholesteremic Agents*/administration & dosage , Anticholesteremic Agents*/therapeutic use , Coronary Artery Disease*/drug therapy , Coronary Artery Disease*/blood , Coronary Artery Disease*/diagnostic imaging , Ezetimibe*/administration & dosage , Ezetimibe*/therapeutic use , Plaque, Atherosclerotic*/drug therapy , Plaque, Atherosclerotic*/diagnostic imaging , Plaque, Atherosclerotic*/blood, Aged ; Female ; Humans ; Male ; Middle Aged ; Cholesterol Ester Transfer Proteins/antagonists & inhibitors ; Cholesterol, LDL/blood ; Coronary Angiography ; Double-Blind Method ; Drug Combinations ; Drug Therapy, Combination

Design, synthesis and biological evaluation of novel dualaction statin conjugates with triglyceride and cholesterol lowering activities.

Autori: Qu Z Liu YC Suo Q a ďalší

Zdroj: Molecular diversity [Mol Divers] 2025 Dec; Vol. 29 (6), pp. 6227-6241. Date of Electronic Publication: 2025 Feb 23.

Spôsob vydávania: Journal Article

Informácie o časopise: Publisher: ESCOM Science Publishers Country of Publication: Netherlands NLM ID: 9516534 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1573-501X (Electronic) Linking ISSN: 13811991 NLM ISO Abbreviation: Mol Divers Subsets: MEDLINE

Výrazy zo slovníka MeSH: Triglycerides*/blood , Triglycerides*/metabolism , Cholesterol*/blood , Cholesterol*/metabolism , Drug Design* , Hydroxymethylglutaryl-CoA Reductase Inhibitors*/pharmacology , Hydroxymethylglutaryl-CoA Reductase Inhibitors*/chemistry , Hydroxymethylglutaryl-CoA Reductase Inhibitors*/chemical synthesis , Anticholesteremic Agents*/pharmacology , Anticholesteremic Agents*/chemistry , Anticholesteremic Agents*/chemical synthesis, Humans ; Structure-Activity Relationship ; Animals

Advancements in lipid-lowering therapy: the role of proprotein convertase subtilisin/kexin type 9 inhibitors and beyond in cardiovascular risk reduction.

Autori: Ruhela N Singla A Trivedi YV a ďalší

Zdroj: Coronary artery disease [Coron Artery Dis] 2025 Dec 01; Vol. 36 (8), pp. 696-706. Date of Electronic Publication: 2025 Oct 29.

Spôsob vydávania: Journal Article; Review

Informácie o časopise: Publisher: Lippincott Williams & Wilkins Country of Publication: England NLM ID: 9011445 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1473-5830 (Electronic) Linking ISSN: 09546928 NLM ISO Abbreviation: Coron Artery Dis Subsets: MEDLINE

Výrazy zo slovníka MeSH: PCSK9 Inhibitors* , Cardiovascular Diseases*/prevention & control , Anticholesteremic Agents*/therapeutic use , Anticholesteremic Agents*/adverse effects , Serine Proteinase Inhibitors*/therapeutic use , Dyslipidemias*/drug therapy , Dyslipidemias*/blood, Humans ; Cholesterol, LDL/blood ; Treatment Outcome ; Heart Disease Risk Factors ; Antibodies, Monoclonal, Humanized ; Proprotein Convertase 9

Targeted hepatic delivery of ezetimibe via red blood cell-coated nanoparticles for the treatment of non-alcoholic fatty liver disease through inflammation modulation.

Autori: Esim O Adatepe S Aksoy OA a ďalší

Zdroj: International journal of pharmaceutics [Int J Pharm] 2025 Nov 30; Vol. 685, pp. 126241. Date of Electronic Publication: 2025 Oct 04.

Spôsob vydávania: Journal Article

Informácie o časopise: Publisher: Elsevier/North-Holland Biomedical Press Country of Publication: Netherlands NLM ID: 7804127 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1873-3476 (Electronic) Linking ISSN: 03785173 NLM ISO Abbreviation: Int J Pharm Subsets: MEDLINE

Výrazy zo slovníka MeSH: Ezetimibe*/administration & dosage , Ezetimibe*/pharmacokinetics , Ezetimibe*/chemistry , Non-alcoholic Fatty Liver Disease*/drug therapy , Non-alcoholic Fatty Liver Disease*/metabolism , Nanoparticles*/chemistry , Nanoparticles*/administration & dosage , Anticholesteremic Agents*/administration & dosage , Anticholesteremic Agents*/pharmacokinetics , Anticholesteremic Agents*/chemistry, Animals ; Polylactic Acid-Polyglycolic Acid Copolymer/chemistry ; Male ; Liver/metabolism ; Liver/drug effects ; Rats ; Rats, Sprague-Dawley ; Drug Liberation ; Tissue Distribution ; Erythrocytes/metabolism ; Diet, High-Fat/adverse effects ; Particle Size ; Drug Delivery Systems/methods ; Erythrocyte Membrane/chemistry ; Polyglycolic Acid/chemistry ; Drug Carriers/chemistry ; Lactic Acid/chemistry

High-Intensity Statin versus Upfront Equivalent-Dose Combination of Moderate-Intensity Statin with Ezetimibe Following Acute Myocardial Infarction (ROSUZET-AMI): protocol of a multicentre, open-label, randomised non-inferiority trial.

Autori: Choo EH Kim CJ Hwang BH a ďalší

Korporácia: Choo EH Kim CJ Hwang BH a ďalší

Zdroj: BMJ open [BMJ Open] 2025 Nov 05; Vol. 15 (11), pp. e104127. Date of Electronic Publication: 2025 Nov 05.

Spôsob vydávania: Journal Article; Clinical Trial Protocol

Informácie o časopise: Publisher: BMJ Publishing Group Ltd Country of Publication: England NLM ID: 101552874 Publication Model: Electronic Cited Medium: Internet ISSN: 2044-6055 (Electronic) Linking ISSN: 20446055 NLM ISO Abbreviation: BMJ Open Subsets: MEDLINE

Výrazy zo slovníka MeSH: Ezetimibe*/administration & dosage , Ezetimibe*/therapeutic use , Myocardial Infarction*/drug therapy , Hydroxymethylglutaryl-CoA Reductase Inhibitors*/administration & dosage , Hydroxymethylglutaryl-CoA Reductase Inhibitors*/therapeutic use , Anticholesteremic Agents*/administration & dosage , Anticholesteremic Agents*/therapeutic use , Rosuvastatin Calcium*/administration & dosage , Rosuvastatin Calcium*/therapeutic use, Humans ; Prospective Studies ; Drug Therapy, Combination ; Cholesterol, LDL/blood ; Cholesterol, LDL/drug effects ; Multicenter Studies as Topic ; Female ; Percutaneous Coronary Intervention ; Male ; Randomized Controlled Trials as Topic ; Middle Aged ; Equivalence Trials as Topic ; Aged ; Treatment Outcome

Population Pharmacokinetics and Exposure-Response Modeling for Evinacumab in Children, Adolescents, and Adults With Homozygous Familial Hypercholesterolemia.

Autori: Bihorel S Dingman R Mendell J a ďalší

Zdroj: CPT: pharmacometrics & systems pharmacology [CPT Pharmacometrics Syst Pharmacol] 2025 Nov; Vol. 14 (11), pp. 1823-1834. Date of Electronic Publication: 2025 Mar 17.

Spôsob vydávania: Journal Article; Randomized Controlled Trial

Informácie o časopise: Publisher: Wiley Country of Publication: United States NLM ID: 101580011 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2163-8306 (Electronic) Linking ISSN: 21638306 NLM ISO Abbreviation: CPT Pharmacometrics Syst Pharmacol Subsets: MEDLINE

Výrazy zo slovníka MeSH: Hyperlipoproteinemia Type II*/drug therapy , Hyperlipoproteinemia Type II*/blood , Hyperlipoproteinemia Type II*/genetics , Models, Biological* , Antibodies, Monoclonal*/pharmacokinetics , Antibodies, Monoclonal*/administration & dosage , Anticholesteremic Agents*/pharmacokinetics , Anticholesteremic Agents*/administration & dosage , Antibodies, Monoclonal, Humanized*/pharmacokinetics, Humans ; Adolescent ; Child ; Adult ; Angiopoietin-Like Protein 3/antagonists & inhibitors ; Male ; Female ; Cholesterol, LDL/blood ; Child, Preschool ; Young Adult ; Angiopoietin-like Proteins/antagonists & inhibitors ; Dose-Response Relationship, Drug ; Middle Aged ; Homozygote

Pushing the limits of LDL cholesterol: Emerging paradigms in cardiovascular risk reduction.

Autori: Yaghoubi D Sallam T

Zdroj: Trends in cardiovascular medicine [Trends Cardiovasc Med] 2025 Nov; Vol. 35 (8), pp. 530-538. Date of Electronic Publication: 2025 Jul 13.

Spôsob vydávania: Journal Article; Review

Informácie o časopise: Publisher: Elsevier Science Publishing Country of Publication: United States NLM ID: 9108337 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1873-2615 (Electronic) Linking ISSN: 10501738 NLM ISO Abbreviation: Trends Cardiovasc Med Subsets: MEDLINE

Výrazy zo slovníka MeSH: Cholesterol, LDL*/blood , Cardiovascular Diseases*/prevention & control , Cardiovascular Diseases*/blood , Cardiovascular Diseases*/epidemiology , Cardiovascular Diseases*/diagnosis , Cardiovascular Diseases*/genetics , Dyslipidemias*/blood , Dyslipidemias*/drug therapy , Dyslipidemias*/diagnosis , Dyslipidemias*/genetics , Dyslipidemias*/epidemiology , Anticholesteremic Agents*/therapeutic use , Anticholesteremic Agents*/adverse effects , Risk Reduction Behavior*, Humans ; Risk Assessment ; Biomarkers/blood ; Treatment Outcome ; Heart Disease Risk Factors ; PCSK9 Inhibitors ; Proprotein Convertase 9

New Oral PCSK9 Inhibitor: "MK-0616".

Autori: Siddiqui Z Frishman W

Zdroj: Cardiology in review [Cardiol Rev] 2025 Nov-Dec 01; Vol. 33 (6), pp. 573-577. Date of Electronic Publication: 2024 Jan 29.

Spôsob vydávania: Journal Article; Review

Informácie o časopise: Publisher: Lippincott Williams & Wilkins Country of Publication: United States NLM ID: 9304686 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1538-4683 (Electronic) Linking ISSN: 10615377 NLM ISO Abbreviation: Cardiol Rev Subsets: MEDLINE

Výrazy zo slovníka MeSH: PCSK9 Inhibitors* , Hypercholesterolemia*/drug therapy , Anticholesteremic Agents*/therapeutic use , Anticholesteremic Agents*/administration & dosage , Peptides, Cyclic*/administration & dosage , Peptides, Cyclic*/therapeutic use, Humans ; Administration, Oral ; Cholesterol, LDL/blood ; Proprotein Convertase 9

Efficacy and Safety of Fimasartan, Atorvastatin, and Ezetimibe Combination Therapy in Patients With Hypertension and Dyslipidemia: A Randomized, Double-Blind, Multicenter, Therapeutic Confirmatory, Phase III Clinical Trial.

Autori: Hong SJ Kim JH Cha KS a ďalší

Zdroj: Clinical therapeutics [Clin Ther] 2025 Nov; Vol. 47 (11), pp. 1028-1036. Date of Electronic Publication: 2025 Sep 14.

Spôsob vydávania: Journal Article; Randomized Controlled Trial; Multicenter Study; Clinical Trial, Phase III

Informácie o časopise: Publisher: Excerpta Medica Country of Publication: United States NLM ID: 7706726 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1879-114X (Electronic) Linking ISSN: 01492918 NLM ISO Abbreviation: Clin Ther Subsets: MEDLINE

Výrazy zo slovníka MeSH: Hypertension*/drug therapy , Hypertension*/complications , Pyrimidines*/adverse effects , Pyrimidines*/therapeutic use , Pyrimidines*/administration & dosage , Atorvastatin*/adverse effects , Atorvastatin*/therapeutic use , Atorvastatin*/administration & dosage , Biphenyl Compounds*/adverse effects , Biphenyl Compounds*/therapeutic use , Biphenyl Compounds*/administration & dosage , Anticholesteremic Agents*/therapeutic use , Anticholesteremic Agents*/adverse effects , Anticholesteremic Agents*/administration & dosage , Tetrazoles*/adverse effects , Tetrazoles*/therapeutic use , Tetrazoles*/administration & dosage , Hypercholesterolemia*/drug therapy , Hypercholesterolemia*/complications , Dyslipidemias*/drug therapy , Dyslipidemias*/complications , Azetidines*/adverse effects , Azetidines*/therapeutic use , Azetidines*/administration & dosage , Antihypertensive Agents*/therapeutic use , Antihypertensive Agents*/adverse effects , Antihypertensive Agents*/administration & dosage, Humans ; Male ; Female ; Middle Aged ; Drug Therapy, Combination ; Double-Blind Method ; Ezetimibe/adverse effects ; Ezetimibe/therapeutic use ; Aged ; Republic of Korea ; Blood Pressure/drug effects ; Treatment Outcome ; Cholesterol, LDL/blood

Comparison of Model-Predicted and Observed Evinacumab Pharmacokinetics and Efficacy in Children Aged < 5 Years With Homozygous Familial Hypercholesterolemia.

Autori: Bihorel S Dingman R Mendell J a ďalší

Zdroj: CPT: pharmacometrics & systems pharmacology [CPT Pharmacometrics Syst Pharmacol] 2025 Nov; Vol. 14 (11), pp. 1835-1847. Date of Electronic Publication: 2025 Mar 17.

Spôsob vydávania: Journal Article; Comparative Study

Informácie o časopise: Publisher: Wiley Country of Publication: United States NLM ID: 101580011 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2163-8306 (Electronic) Linking ISSN: 21638306 NLM ISO Abbreviation: CPT Pharmacometrics Syst Pharmacol Subsets: MEDLINE

Výrazy zo slovníka MeSH: Hyperlipoproteinemia Type II*/drug therapy , Hyperlipoproteinemia Type II*/blood , Antibodies, Monoclonal*/pharmacokinetics , Antibodies, Monoclonal*/administration & dosage , Antibodies, Monoclonal*/therapeutic use , Models, Biological* , Antibodies, Monoclonal, Humanized*/pharmacokinetics , Antibodies, Monoclonal, Humanized*/administration & dosage , Anticholesteremic Agents*/pharmacokinetics , Anticholesteremic Agents*/administration & dosage , Anticholesteremic Agents*/therapeutic use, Humans ; Child, Preschool ; Cholesterol, LDL/blood ; Male ; Female ; Infant ; Treatment Outcome ; Angiopoietin-Like Protein 3/antagonists & inhibitors ; Infusions, Intravenous ; Body Weight

Synthesis and lipid-lowering activities of preussin derivatives.

Autori: Tadpetch K Thongpat K Jeensrikong N a ďalší

Zdroj: Bioorganic & medicinal chemistry [Bioorg Med Chem] 2025 Nov 01; Vol. 129, pp. 118336. Date of Electronic Publication: 2025 Jul 30.

Spôsob vydávania: Journal Article

Informácie o časopise: Publisher: Elsevier Science Country of Publication: England NLM ID: 9413298 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1464-3391 (Electronic) Linking ISSN: 09680896 NLM ISO Abbreviation: Bioorg Med Chem Subsets: MEDLINE

Výrazy zo slovníka MeSH: Pyrrolidines*/pharmacology , Pyrrolidines*/chemical synthesis , Pyrrolidines*/chemistry , Anticholesteremic Agents*/chemical synthesis , Anticholesteremic Agents*/pharmacology , Anticholesteremic Agents*/chemistry , Hypolipidemic Agents*/chemical synthesis , Hypolipidemic Agents*/pharmacology , Hypolipidemic Agents*/chemistry, Humans ; Caco-2 Cells ; Hep G2 Cells ; Structure-Activity Relationship ; Molecular Structure ; Lipid Metabolism/drug effects ; Cholesterol/metabolism ; Dose-Response Relationship, Drug

Proprotein Convertase Subtilisin / Kexin Type 9 ( PCSK9 ) Inhibitor Therapy Reduces the Level of DNA Damage in Patients with Heterozygous Familial Hypercholesterolemia.

Autori: Woźniak E Woźniak A Pawlos A a ďalší

Zdroj: International journal of molecular sciences [Int J Mol Sci] 2025 Oct 29; Vol. 26 (21). Date of Electronic Publication: 2025 Oct 29.

Spôsob vydávania: Journal Article

Informácie o časopise: Publisher: MDPI Country of Publication: Switzerland NLM ID: 101092791 Publication Model: Electronic Cited Medium: Internet ISSN: 1422-0067 (Electronic) Linking ISSN: 14220067 NLM ISO Abbreviation: Int J Mol Sci Subsets: MEDLINE

Výrazy zo slovníka MeSH: Hyperlipoproteinemia Type II*/drug therapy , Hyperlipoproteinemia Type II*/genetics , Hyperlipoproteinemia Type II*/blood , DNA Damage*/drug effects , PCSK9 Inhibitors* , Anticholesteremic Agents*/therapeutic use , Anticholesteremic Agents*/pharmacology, Humans ; Male ; Female ; Middle Aged ; Adult ; Proprotein Convertase 9/metabolism ; Proprotein Convertase 9/genetics ; Heterozygote ; Antibodies, Monoclonal, Humanized/therapeutic use ; Cholesterol, LDL/blood

Recaticimab in adult heterozygous familial hypercholesterolaemia (REMAIN-3): a multicentre, randomized, double-blind, placebo-controlled Phase 3 study.

Autori: Li L Zhou Y Deng C a ďalší

Zdroj: Cardiovascular research [Cardiovasc Res] 2025 Oct 24; Vol. 121 (12), pp. 1856-1864.

Spôsob vydávania: Journal Article; Multicenter Study; Randomized Controlled Trial; Clinical Trial, Phase III

Informácie o časopise: Publisher: Oxford Journals Country of Publication: England NLM ID: 0077427 Publication Model: Print Cited Medium: Internet ISSN: 1755-3245 (Electronic) Linking ISSN: 00086363 NLM ISO Abbreviation: Cardiovasc Res Subsets: MEDLINE

Výrazy zo slovníka MeSH: Hyperlipoproteinemia Type II*/drug therapy , Hyperlipoproteinemia Type II*/blood , Hyperlipoproteinemia Type II*/genetics , Hyperlipoproteinemia Type II*/diagnosis , Cholesterol, LDL*/blood , Antibodies, Monoclonal, Humanized*/adverse effects , Antibodies, Monoclonal, Humanized*/therapeutic use , PCSK9 Inhibitors* , Anticholesteremic Agents*/adverse effects , Anticholesteremic Agents*/therapeutic use, Humans ; Double-Blind Method ; Female ; Male ; Middle Aged ; Adult ; Treatment Outcome ; Heterozygote ; China ; Time Factors ; Proprotein Convertase 9/metabolism ; Proprotein Convertase 9/immunology ; Biomarkers/blood

Challenges in the Choice of Nonstatin Medications for Low-Density Lipoprotein-C Lowering for Cardiovascular Risk Reduction.

Autori: Myerson M Warden BA Saseen JJ a ďalší

Zdroj: Journal of the American Heart Association [J Am Heart Assoc] 2025 Oct 21; Vol. 14 (20), pp. e044134. Date of Electronic Publication: 2025 Oct 09.

Spôsob vydávania: Journal Article; Review

Informácie o časopise: Publisher: Wiley-Blackwell Country of Publication: England NLM ID: 101580524 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2047-9980 (Electronic) Linking ISSN: 20479980 NLM ISO Abbreviation: J Am Heart Assoc Subsets: MEDLINE

Výrazy zo slovníka MeSH: Cholesterol, LDL*/blood , Cardiovascular Diseases*/prevention & control , Cardiovascular Diseases*/blood , Cardiovascular Diseases*/epidemiology , Anticholesteremic Agents*/therapeutic use , Anticholesteremic Agents*/adverse effects , Dyslipidemias*/drug therapy , Dyslipidemias*/blood , Dyslipidemias*/diagnosis, Humans ; PCSK9 Inhibitors ; Heart Disease Risk Factors ; Hydroxymethylglutaryl-CoA Reductase Inhibitors/therapeutic use ; Treatment Outcome ; Biomarkers/blood ; Proprotein Convertase 9 ; Dicarboxylic Acids ; Fatty Acids

Oxidized phospholipid dynamics in the early post-infarction period: Effects of PCSK9 inhibition with evolocumab.

Autori: Atallah M Harb T Nasrallah N a ďalší

Zdroj: Atherosclerosis [Atherosclerosis] 2025 Oct; Vol. 409, pp. 120469. Date of Electronic Publication: 2025 Aug 05.

Spôsob vydávania: Clinical Trial, Phase II; Journal Article; Randomized Controlled Trial

Informácie o časopise: Publisher: Elsevier Country of Publication: Ireland NLM ID: 0242543 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1879-1484 (Electronic) Linking ISSN: 00219150 NLM ISO Abbreviation: Atherosclerosis Subsets: MEDLINE

Výrazy zo slovníka MeSH: Antibodies, Monoclonal, Humanized*/therapeutic use , Antibodies, Monoclonal, Humanized*/adverse effects , Anticholesteremic Agents*/therapeutic use , Anticholesteremic Agents*/adverse effects , Non-ST Elevated Myocardial Infarction*/blood , Non-ST Elevated Myocardial Infarction*/drug therapy , Non-ST Elevated Myocardial Infarction*/diagnosis , PCSK9 Inhibitors* , Phospholipids*/blood , Serine Proteinase Inhibitors*/therapeutic use , Serine Proteinase Inhibitors*/adverse effects , ST Elevation Myocardial Infarction*/blood , ST Elevation Myocardial Infarction*/drug therapy , ST Elevation Myocardial Infarction*/diagnosis, Aged ; Female ; Humans ; Male ; Middle Aged ; Apolipoprotein B-100/blood ; Biomarkers/blood ; Cholesterol, LDL/blood ; Double-Blind Method ; Lipoprotein(a)/blood ; Oxidation-Reduction ; Proprotein Convertase 9/metabolism ; Time Factors ; Treatment Outcome

Targeting drug-resistant cancers: in silico repurposing of the cholesterol-lowering drug Ezetimibe for selective inhibition of aldo-keto reductase 1B10 (AKR1B10).

Autori: Alkhalaf HJ Abdulrazzak Al Shehadeh J Alshjai MK a ďalší

Zdroj: SAR and QSAR in environmental research [SAR QSAR Environ Res] 2025 Oct; Vol. 36 (10), pp. 875-908. Date of Electronic Publication: 2025 Oct 23.

Spôsob vydávania: Journal Article

Informácie o časopise: Publisher: Taylor & Francis Country of Publication: England NLM ID: 9440156 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1029-046X (Electronic) Linking ISSN: 1026776X NLM ISO Abbreviation: SAR QSAR Environ Res Subsets: MEDLINE

Výrazy zo slovníka MeSH: Ezetimibe*/pharmacology , Ezetimibe*/chemistry , Drug Repositioning* , Aldo-Keto Reductases*/antagonists & inhibitors , Drug Resistance, Neoplasm*/drug effects , Anticholesteremic Agents*/pharmacology , Anticholesteremic Agents*/chemistry , Enzyme Inhibitors*/chemistry , Enzyme Inhibitors*/pharmacology, Molecular Docking Simulation ; Humans ; Computer Simulation

Effectiveness and Safety of Very-Low-Dose Rosuvastatin-Ezetimibe Therapy in Korean Patients with Dyslipidaemia: A Multicentre Prospective Observational Study.

Autori: Roh JW Park MH Son JW a ďalší

Korporácia: Roh JW Park MH Son JW a ďalší

Zdroj: Clinical drug investigation [Clin Drug Investig] 2025 Oct; Vol. 45 (10), pp. 803-813. Date of Electronic Publication: 2025 Sep 16.

Spôsob vydávania: Journal Article; Multicenter Study; Observational Study

Informácie o časopise: Publisher: Adis, Springer International Country of Publication: New Zealand NLM ID: 9504817 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1179-1918 (Electronic) Linking ISSN: 11732563 NLM ISO Abbreviation: Clin Drug Investig Subsets: MEDLINE

Výrazy zo slovníka MeSH: Rosuvastatin Calcium*/administration & dosage , Rosuvastatin Calcium*/adverse effects , Rosuvastatin Calcium*/therapeutic use , Ezetimibe*/administration & dosage , Ezetimibe*/adverse effects , Ezetimibe*/therapeutic use , Dyslipidemias*/drug therapy , Dyslipidemias*/blood , Anticholesteremic Agents*/administration & dosage , Anticholesteremic Agents*/adverse effects, Humans ; Male ; Female ; Middle Aged ; Prospective Studies ; Republic of Korea ; Aged ; Cholesterol, LDL/blood ; Drug Therapy, Combination ; Treatment Outcome ; Adult ; Hydroxymethylglutaryl-CoA Reductase Inhibitors/administration & dosage ; Hydroxymethylglutaryl-CoA Reductase Inhibitors/adverse effects ; Dose-Response Relationship, Drug